Q3 2024 · 13F-HR
BVF INC/ILholdings as filed
Filed 2024-11-14 · accession 0000921895-24-002698
$3.42B
Reported value
55
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $1.10B | 32.1% | 21,751,284 | Common | SHARED |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $244.3M | 7.15% | 5,161,801 | Common | SHARED |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $157.8M | 4.61% | 3,478,612 | Common | SHARED |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $120.0M | 3.51% | 3,075,907 | Common | SHARED |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $109.6M | 3.21% | 4,661,194 | Common | SHARED |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $109.1M | 3.19% | 9,135,893 | Common | SHARED |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $98.3M | 2.87% | 2,238,986 | Common | SHARED |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $96.3M | 2.82% | 5,750,683 | Common | SHARED |
| 98419J206 | XOMA | XOMA ROYALTY CORPORATION | $96.2M | 2.81% | 3,633,743 | Common | SHARED |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $94.0M | 2.75% | 1,046,000 | Common | SHARED |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $83.3M | 2.44% | 1,850,167 | Common | SHARED |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $79.8M | 2.33% | 7,382,642 | Common | SHARED |
| H00263105 | ACIU | AC IMMUNE SA | $73.8M | 2.16% | 19,522,436 | Common | SHARED |
| G3855L106 | GHRS | GH RESEARCH PLC | $69.6M | 2.04% | 10,400,158 | Common | SHARED |
| 50127T109 | KURA | KURA ONCOLOGY INC | $65.9M | 1.93% | 3,371,761 | Common | SHARED |
| 88427A107 | — | THIRD HARMONIC BIO INC | $59.2M | 1.73% | 4,365,933 | Common | SHARED |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $58.2M | 1.70% | 1,451,879 | Common | SHARED |
| 98985Y108 | ZYME | ZYMEWORKS INC | $57.8M | 1.69% | 4,607,935 | Common | SHARED |
| 29668H708 | EPIEUR | ESSA PHARMA INC | $53.0M | 1.55% | 8,748,629 | Common | SHARED |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $52.9M | 1.55% | 1,190,107 | Common | SHARED |
| 15102K100 | CELC | CELCUITY INC | $51.7M | 1.51% | 3,466,000 | Common | SHARED |
| 282559103 | ETNBGBP | 89BIO INC | $50.4M | 1.47% | 6,811,631 | Common | SHARED |
| 344174107 | FHTX | FOGHORN THERAPEUTICS INC | $49.4M | 1.44% | 5,302,000 | Common | SHARED |
| 36315X101 | LKFT | GALAPAGOS NV | $45.2M | 1.32% | 1,569,422 | Common | SHARED |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $44.7M | 1.31% | 1,409,993 | Common | SHARED |
| 03589W102 | ANNX | ANNEXON INC | $41.4M | 1.21% | 7,000,000 | Common | SHARED |
| 156944100 | CGON | CG ONCOLOGY INC | $37.5M | 1.10% | 994,596 | Common | SHARED |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $35.5M | 1.04% | 10,333,600 | Common | SHARED |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $25.3M | 0.74% | 1,521,948 | Common | SHARED |
| 98401F105 | XNCR | XENCOR INC | $17.1M | 0.50% | 850,000 | Common | SHARED |
| 28617K101 | ELDN | ELEDON PHARMACEUTICALS INC | $15.7M | 0.46% | 6,293,282 | Common | SHARED |
| 89854M101 | TCRX | TSCAN THERAPEUTICS INC | $14.9M | 0.44% | 2,989,474 | Common | SHARED |
| 29286M105 | — | ENGENE HOLDINGS INC | $14.9M | 0.43% | 2,251,037 | Common | SHARED |
| 4525EP101 | VTLUSD | IMMUNIC INC | $14.7M | 0.43% | 8,902,972 | Common | SHARED |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $10.8M | 0.32% | 16,552,417 | Common | SHARED |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $9.1M | 0.27% | 967,000 | Common | SHARED |
| 45175G108 | — | IKENA ONCOLOGY INC | $8.3M | 0.24% | 4,769,164 | Common | SHARED |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $7.6M | 0.22% | 703,065 | Common | SHARED |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $6.2M | 0.18% | 5,228,461 | Common | SHARED |
| 92673K108 | VIGL | VIGIL NEUROSCIENCE INC | $6.2M | 0.18% | 1,813,633 | Common | SHARED |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $6.0M | 0.18% | 2,000,000 | Common | SHARED |
| 92337C203 | VSTM | VERASTEM INC | $5.0M | 0.15% | 1,685,219 | Common | SHARED |
| 690469101 | OVID | OVID THERAPEUTICS INC | $4.5M | 0.13% | 3,853,818 | Common | SHARED |
| 720795202 | — | PIERIS PHARMACEUTICALS INC | $4.3M | 0.13% | 257,626 | Common | SHARED |
| 92539P101 | — | VERVE THERAPEUTICS INC | $3.1M | 0.09% | 650,000 | Common | SHARED |
| 78397T202 | SABS | SAB BIOTHERAPEUTICS INC | $2.5M | 0.07% | 917,826 | Common | SHARED |
| 60853G106 | MOLN | MOLECULAR PARTNERS AG | $2.1M | 0.06% | 443,221 | Common | SHARED |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $1.8M | 0.05% | 2,966,836 | Common | SHARED |
| 38000Q102 | GLYCEUR | GLYCOMIMETICS INC | $1.6M | 0.05% | 9,544,262 | Common | SHARED |
| 46124U107 | IVA | INVENTIVA SA | $1.3M | 0.04% | 686,040 | Common | SHARED |
| 88032L605 | TENX | TENAX THERAPEUTICS INC | $1.2M | 0.03% | 339,549 | Common | SHARED |
| 29286M113 | — | ENGENE HOLDINGS INC | $803,686 | 0.02% | 945,402 | Common | SHARED |
| 608550208 | MTEMEUR | MOLECULAR TEMPLATES INC | $733,744 | 0.02% | 522,238 | Common | SHARED |
| H57830137 | — | NLS PHARMACEUTICS LTD | $728,437 | 0.02% | 143,676 | Common | SHARED |
| 34962G208 | FBRX | FORTE BIOSCIENCES INC | $667,979 | 0.02% | 119,282 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.